MCID: CMP040
MIFTS: 35

Complement Component 4, Partial Deficiency of

Categories: Blood diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Complement Component 4, Partial Deficiency of

MalaCards integrated aliases for Complement Component 4, Partial Deficiency of:

Name: Complement Component 4, Partial Deficiency of 58 30 13 41
C1 Inhibitor Deficiency 60
Angioedemas, Hereditary 74

Characteristics:

Orphanet epidemiological data:

60
c1 inhibitor deficiency
Inheritance: Autosomal dominant;

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
complement component 4, partial deficiency of:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 60  
Rare immunological diseases


External Ids:

OMIM 58 120790
ICD10 via Orphanet 35 D84.1
Orphanet 60 ORPHA459353
MedGen 43 C1852700
SNOMED-CT via HPO 70 263681008 55464009
UMLS 74 C0019243

Summaries for Complement Component 4, Partial Deficiency of

MalaCards based summary : Complement Component 4, Partial Deficiency of, also known as c1 inhibitor deficiency, is related to c1 inhibitor deficiency and hereditary angioedema with c1inh deficiency. An important gene associated with Complement Component 4, Partial Deficiency of is SERPING1 (Serpin Family G Member 1). The drugs Icatibant and Omalizumab have been mentioned in the context of this disorder. Affiliated tissues include myeloid, testes and b cells, and related phenotype is systemic lupus erythematosus.

Description from OMIM: 120790

Related Diseases for Complement Component 4, Partial Deficiency of

Diseases related to Complement Component 4, Partial Deficiency of via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 24)
# Related Disease Score Top Affiliating Genes
1 c1 inhibitor deficiency 12.6
2 hereditary angioedema with c1inh deficiency 11.8
3 hereditary angioedema 11.7
4 acquired angioedema 11.7
5 acquired angioedema with c1inh deficiency 11.3
6 angioedema 10.8
7 lupus erythematosus 10.3
8 systemic lupus erythematosus 10.2
9 lymphoma 10.1
10 melkersson-rosenthal syndrome 9.9
11 rheumatoid arthritis 9.9
12 sjogren syndrome 9.9
13 autoimmune lymphoproliferative syndrome, type v 9.9
14 arthritis 9.9
15 b-cell lymphomas 9.9
16 crohn's disease 9.9
17 marginal zone b-cell lymphoma 9.9
18 dermatomyositis 9.9
19 capillary leak syndrome 9.9
20 antiphospholipid syndrome 9.9
21 lymphosarcoma 9.9
22 neuropathy 9.9
23 systemic capillary leak syndrome 9.9
24 hereditary angioedema with normal c1inh 9.9

Graphical network of the top 20 diseases related to Complement Component 4, Partial Deficiency of:



Diseases related to Complement Component 4, Partial Deficiency of

Symptoms & Phenotypes for Complement Component 4, Partial Deficiency of

Human phenotypes related to Complement Component 4, Partial Deficiency of:

33
# Description HPO Frequency HPO Source Accession
1 systemic lupus erythematosus 33 HP:0002725

Symptoms via clinical synopsis from OMIM:

58
Immunology:
systemic lupus erythematosus
partial c4 deficiency

Clinical features from OMIM:

120790

Drugs & Therapeutics for Complement Component 4, Partial Deficiency of

Drugs for Complement Component 4, Partial Deficiency of (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Icatibant Approved, Investigational Phase 4,Phase 3,Phase 1 130308-48-4, 138614-30-9 71364
2
Omalizumab Approved, Investigational Phase 4 242138-07-4
3
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
4
Bradykinin Investigational Phase 4,Phase 3,Phase 1 58-82-2 439201
5
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
6 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
8 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
9 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
10 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Complement C1s Phase 4,Phase 3,Phase 2,Phase 1
13 Complement C1 Inactivator Proteins Phase 4,Phase 3,Phase 2,Phase 1
14 Complement C1 Inhibitor Protein Phase 4,Phase 3,Phase 2,Phase 1
15 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1
17 Complement Inactivating Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Complement System Proteins Phase 4,Phase 3,Phase 2,Phase 1
19 Bradykinin Receptor Antagonists Phase 4,Phase 3,Phase 1
20 Kininogens Phase 4,Phase 3,Phase 1
21 Bradykinin B2 Receptor Antagonists Phase 4,Phase 3,Phase 1
22 Vasodilator Agents Phase 4,Phase 3,Phase 1
23 Antibodies Phase 4,Phase 2,Phase 1
24 Immunoglobulins Phase 4,Phase 2,Phase 1
25 Anti-Allergic Agents Phase 4
26 Anti-Asthmatic Agents Phase 4
27 Respiratory System Agents Phase 4
28 Immunoglobulins, Intravenous Phase 4
29 gamma-Globulins Phase 4
30 Rho(D) Immune Globulin Phase 4
31 Ecallantide Approved, Investigational Phase 3,Phase 2 460738-38-9
32
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
33
tannic acid Approved Phase 3 1401-55-4
34
Tranexamic Acid Approved Phase 3 1197-18-8 5526
35 Pharmaceutical Solutions Phase 3,Phase 2
36 Coagulants Phase 3,Phase 2
37 Fibrinolytic Agents Phase 3,Not Applicable
38 Antifibrinolytic Agents Phase 3
39 Hemostatics Phase 3
40 Kallikreins Phase 3,Phase 2,Phase 1
41 Plasma Kallikrein Phase 3,Phase 2,Phase 1
42 Passionflower Phase 3
43
Danazol Approved Phase 2 17230-88-5 28417
44 Hormone Antagonists Phase 2,Phase 1
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1
46 Hormones Phase 2,Phase 1
47 Fertility Agents Phase 2
48 Antineoplastic Agents, Immunological Phase 2
49 Antibodies, Monoclonal Phase 2,Phase 1
50 Plasminogen Phase 2

Interventional clinical trials:

(show top 50) (show all 90)
# Name Status NCT ID Phase Drugs
1 A Call Center During HAE Attacks (SOS HAE) Completed NCT01679912 Phase 4
2 C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation Withdrawn NCT01151735 Phase 4 C-1-esterase;C-1-esterase;placebo
3 Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE Completed NCT01457430 Phase 4 Icatibant
4 A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE Completed NCT00914966 Phase 4
5 Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert Completed NCT01467947 Phase 4
6 Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy Recruiting NCT02966314 Phase 4 Omalizumab;Placebos
7 A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions Recruiting NCT03576469 Phase 4
8 A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema Completed NCT01912456 Phase 3
9 Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks Completed NCT00438815 Phase 3
10 Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks Completed NCT00462709 Phase 3
11 A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema Completed NCT01386658 Phase 3 icatibant
12 A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants Completed NCT03888755 Phase 3 Icatibant
13 Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema Terminated NCT02670720 Phase 3 avoralstat
14 Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema Completed NCT02584959 Phase 3 C1 esterase inhibitor [human] liquid;Placebo
15 Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE Completed NCT02586805 Phase 3 DX-2930 - 300mg/2wk;DX-2930 - 300mg/4wk;DX-2930 - 150mg/4wk;Placebo
16 A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3) Completed NCT00912093 Phase 3 Icatibant;Placebo
17 Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema Completed NCT02052141 Phase 3
18 A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema Completed NCT02316353 Phase 3
19 Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) Completed NCT00456508 Phase 3 ecallantide
20 Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00457015 Phase 3 ecallantide;Phosphate Buffer Saline (PBS), pH 7.0
21 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00225147 Phase 2, Phase 3 Recombinant Human C1 Inhibitor;placebo
22 A Long Term Safety Study of BCX7353 in Hereditary Angioedema Recruiting NCT03472040 Phase 2, Phase 3 BCX7353
23 Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE) Completed NCT02865720 Phase 3 CINRYZE 500 U;CINRYZE 1000 U
24 C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks Completed NCT01005888 Phase 3 Placebo (saline)
25 C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study) Completed NCT00292981 Phase 3 C1 Esterase Inhibitor
26 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00262301 Phase 3 recombinant human C1 inhibitor;Placebo
27 Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks Completed NCT00168103 Phase 2, Phase 3
28 Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00500656 Phase 3 Icatibant;Tranexamic Acid;Oral Placebo;S.C. Placebo
29 Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema Withdrawn NCT01253382 Phase 2, Phase 3
30 Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00262080 Phase 3 ecallantide;Phosphate Buffer Saline (PBS),
31 Berinert P Study of Subcutaneous Versus Intravenous Administration Completed NCT00748202 Phase 3 C1-Esterase Inhibitor
32 Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema Completed NCT00097695 Phase 3 Icatibant;Placebo
33 EASSI - Evaluation of the Safety of Self-Administration With Icatibant Completed NCT00997204 Phase 3 Icatibant
34 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks Completed NCT02303626 Phase 2, Phase 3 BCX4161;Placebo
35 Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE Active, not recruiting NCT02741596 Phase 3 DX-2930;DX-2930
36 C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks Completed NCT00289211 Phase 3 Placebo (saline)
37 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00262288 Phase 2, Phase 3 i.v. recombinant human C1 inhibitor
38 Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan Recruiting NCT03873116 Phase 3 BCX7353 capsules;BCX7353 capsules;Placebo oral capsule
39 Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks Completed NCT01188564 Phase 3 rhC1INH;Placebo (Saline)
40 Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE Active, not recruiting NCT03485911 Phase 3 BCX7353 capsules;Placebo oral capsule
41 C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125151 Phase 3 C1 inhibitor concentrate (C1-esteraseremmer-N)
42 C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125541 Phase 2, Phase 3 C1 inhibitor concentrate (C1-esteraseremmer-N)
43 Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema Unknown status NCT01832896 Phase 2 Ecallantide subcutaneous dosing
44 Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema Recruiting NCT03240133 Phase 2 BCX7353;Placebo
45 Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema Completed NCT02870972 Phase 2 BCX7353;Placebo
46 CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12 Completed NCT01095510 Phase 2
47 A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) Recruiting NCT03712228 Phase 2 Placebo
48 Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients Completed NCT01359969 Phase 2 rhC1INH
49 Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE Completed NCT01984788 Phase 2 BCX4161;Placebo
50 A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase Completed NCT01426763 Phase 2

Search NIH Clinical Center for Complement Component 4, Partial Deficiency of

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Complement Component 4, Partial Deficiency of

Genetic tests related to Complement Component 4, Partial Deficiency of:

# Genetic test Affiliating Genes
1 Complement Component 4, Partial Deficiency of 30 SERPING1

Anatomical Context for Complement Component 4, Partial Deficiency of

MalaCards organs/tissues related to Complement Component 4, Partial Deficiency of:

42
Myeloid, Testes, B Cells, Colon, Spleen, Whole Blood, Small Intestine

Publications for Complement Component 4, Partial Deficiency of

Articles related to Complement Component 4, Partial Deficiency of:

(show top 50) (show all 193)
# Title Authors Year
1
Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate. ( 30866985 )
2019
2
Serum fetuin-A, tumor necrosis factor alpha and C-reactive protein concentrations in patients with hereditary angioedema with C1-inhibitor deficiency. ( 30885236 )
2019
3
Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies. ( 30539362 )
2019
4
Delayed Diagnosis of Hereditary Angioedema with C1-inhibitor Deficiency in Iranian Children and Adolescents. ( 30690789 )
2019
5
Cost-Effectiveness of Prophylactic Medications for the Treatment of Hereditary Angioedema Due to C1 Inhibitor Deficiency: A Real-World U.S. Perspective. ( 30698094 )
2019
6
Hereditary angioedema due to C1-inhibitor deficiency in Macedonia: clinical characteristics, novel SERPING1 mutations and genetic factors modifying the clinical phenotype. ( 29513108 )
2018
7
Targeted next-generation sequencing for the molecular diagnosis of hereditary angioedema due to C1-inhibitor deficiency. ( 29753808 )
2018
8
Icatibant for the treatment of hereditary angioedema with C1-inhibitor deficiency in adolescents and in children aged over 2 years. ( 29757016 )
2018
9
Intermittent C1-Inhibitor Deficiency Associated with Recessive Inheritance: Functional and Structural Insight. ( 29343682 )
2018
10
Long term effects upon rituximab treatment of acquired angio-edema due to c1-inhibitor deficiency. ( 30488963 )
2018
11
Flow-mediated vasodilation assay indicates no endothelial dysfunction in hereditary angioedema patients with C1-inhibitor deficiency. ( 30312677 )
2018
12
Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency. ( 30333824 )
2018
13
Nine year follow-up of a rare case of angioedema due to acquired C1-inhibitor deficiency with late onset and good response to attenuated androgen. ( 30386386 )
2018
14
The diagnosis of hereditary angioedema with C1 inhibitor deficiency: a survey of Canadian physicians and laboratories. ( 30479631 )
2018
15
Genotype-phenotype correlations in Brazilian patients with hereditary angioedema due to C1 inhibitor deficiency. ( 30556912 )
2018
16
Splenic marginal zone lymphomas in acquired C1-inhibitor deficiency: clinical and molecular characterization. ( 30073422 )
2018
17
Secreted Phospholipases A2 in Hereditary Angioedema With C1-Inhibitor Deficiency. ( 30083168 )
2018
18
Long-term prophylaxis therapy in patients with hereditary angioedema with C1 inhibitor deficiency. ( 30056152 )
2018
19
Emotional processes and stress in children affected by hereditary angioedema with C1-inhibitor deficiency: a multicenter, prospective study. ( 30005674 )
2018
20
Clinical and biological response to rituximab treatment in 3 patients with acquired C1-inhibitor deficiency. ( 28866304 )
2017
21
Acquired C1 Inhibitor Deficiency. ( 28687105 )
2017
22
Diagnosis, Course, and Management of Angioedema in Patients With Acquired C1-Inhibitor Deficiency. ( 28284781 )
2017
23
Glucocorticoid receptor gene polymorphisms in hereditary angioedema with C1-inhibitor deficiency. ( 28069032 )
2017
24
Pharmacological Management of Hereditary Angioedema with C1-Inhibitor Deficiency in Pediatric Patients. ( 29214395 )
2017
25
Genetic Determinants of C1 Inhibitor Deficiency Angioedema Age of Onset. ( 29130992 )
2017
26
Treatment of hereditary angioedema due to C1 inhibitor deficiency in Argentina. ( 28825570 )
2017
27
Hereditary C1 inhibitor deficiency is associated with high spontaneous amidase activity. ( 28222330 )
2017
28
Electroconvulsive Therapy in Patients with C1 Inhibitor Deficiency: A Major or Minor Procedure? ( 27326990 )
2016
29
Management of Pregnancy and Delivery in Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency. ( 27326983 )
2016
30
Bacteriuria increases the risk of edematous attacks in hereditary angioedema with C1-inhibitor deficiency. ( 27548887 )
2016
31
Frequent life-threatening laryngeal attacks in two Croatian families with hereditary angioedema due to C1 inhibitor deficiency harbouring a novel frameshift mutation in SERPING1. ( 27187751 )
2016
32
International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. ( 27503784 )
2016
33
Hereditary angio-oedema with C1 inhibitor deficiency: Characteristics and diagnostic delay of Czech patients from one centre. ( 26796857 )
2016
34
Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency. ( 27940765 )
2016
35
Thyroid hormones and complement parameters in hereditary angioedema with C1-inhibitor deficiency. ( 27364943 )
2016
36
Hereditary angioedema due to C1 - inhibitor deficiency in Switzerland: clinical characteristics and therapeutic modalities within a cohort study. ( 27101900 )
2016
37
Prophylaxis in hereditary angioedema (HAE) with C1 inhibitor deficiency. ( 26972189 )
2016
38
Cases of acquired C1 inhibitor deficiency treated with rituximab. ( 27130715 )
2016
39
High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study. ( 27686124 )
2016
40
Delayed diagnosis of C1-inhibitor deficiency associated with significant morbidity and mortality. ( 27727922 )
2016
41
A nationwide study of acquired C1-inhibitor deficiency in France: Characteristics and treatment responses in 92 patients. ( 27537564 )
2016
42
Diagnostic and therapeutic management of hereditary angioedema due to C1-inhibitor deficiency: the Italian experience. ( 26106828 )
2015
43
Comprehensive study into the activation of the plasma enzyme systems during attacks of hereditary angioedema due to C1-inhibitor deficiency. ( 26452350 )
2015
44
Benefits of hydroxychloroquine in the treatment of a patient with angioedema due to acquired C1 inhibitor deficiency. ( 25457864 )
2015
45
The safety of treatments for angioedema with hereditary C1 inhibitor deficiency. ( 26429506 )
2015
46
Correction: A Nationwide Study of Norwegian Patients with Hereditary Angioedema with C1 Inhibitor Deficiency Identified Six Novel Mutations in SERPING1. ( 26270546 )
2015
47
Neutrophil activation during attacks in patients with hereditary angioedema due to C1-inhibitor deficiency. ( 26654922 )
2015
48
Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE). ( 25669442 )
2015
49
A Nationwide Study of Norwegian Patients with Hereditary Angioedema with C1 Inhibitor Deficiency Identified Six Novel Mutations in SERPING1. ( 26154504 )
2015
50
Efficacy of on-demand treatment in reducing morbidity in patients with hereditary angioedema due to C1 inhibitor deficiency. ( 26304015 )
2015

Variations for Complement Component 4, Partial Deficiency of

Expression for Complement Component 4, Partial Deficiency of

Search GEO for disease gene expression data for Complement Component 4, Partial Deficiency of.

Pathways for Complement Component 4, Partial Deficiency of

GO Terms for Complement Component 4, Partial Deficiency of

Sources for Complement Component 4, Partial Deficiency of

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....